Observations on the short-term 'natural history' of probable Alzheimer's disease in a controlled clinical trial

David S Knopman, Stephen Gracon

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We examined the performance of patients with probable Alzheimer's disease (AD) who participated in the placebo arm of a 12-week clinical trial. Assessments occurred at baseline and at 4, 6, 10, and 12 weeks after starting study medication. Patients received the Alzheimer's Disease Assessment Scale- Cognitive on all five occasions and the Mini-Mental State Examination on three occasions (baseline, week 6, and week 12). Their primary caregivers completed the Progressive Deterioration Scale on all five visits. This self- administered questionnaire consists of 29 items regarding the patient's behavioral and functional status. The extrapolated yearly rate of change of the mental status examinations was considerably smaller than expected compared with uncontrolled natural history studies. In addition, there was a large within-subject variability on all three measures. Scores from the baseline assessments contributed more to the variability than did the later assessments. The small magnitude of change, as well as the large between- subjects and within-subject variability, points out the methodologic drawbacks of short-duration therapeutic trials in patients with AD and the challenges in demonstrating reliable treatment effects for potential therapeutic agents.

Original languageEnglish (US)
Pages (from-to)260-265
Number of pages6
JournalNeurology
Volume44
Issue number2
StatePublished - Feb 1994
Externally publishedYes

Fingerprint

Controlled Clinical Trials
Natural History
Alzheimer Disease
Therapeutic Uses
Caregivers
Placebos
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Observations on the short-term 'natural history' of probable Alzheimer's disease in a controlled clinical trial. / Knopman, David S; Gracon, Stephen.

In: Neurology, Vol. 44, No. 2, 02.1994, p. 260-265.

Research output: Contribution to journalArticle

@article{3f5810e239df41e690f976def2c47469,
title = "Observations on the short-term 'natural history' of probable Alzheimer's disease in a controlled clinical trial",
abstract = "We examined the performance of patients with probable Alzheimer's disease (AD) who participated in the placebo arm of a 12-week clinical trial. Assessments occurred at baseline and at 4, 6, 10, and 12 weeks after starting study medication. Patients received the Alzheimer's Disease Assessment Scale- Cognitive on all five occasions and the Mini-Mental State Examination on three occasions (baseline, week 6, and week 12). Their primary caregivers completed the Progressive Deterioration Scale on all five visits. This self- administered questionnaire consists of 29 items regarding the patient's behavioral and functional status. The extrapolated yearly rate of change of the mental status examinations was considerably smaller than expected compared with uncontrolled natural history studies. In addition, there was a large within-subject variability on all three measures. Scores from the baseline assessments contributed more to the variability than did the later assessments. The small magnitude of change, as well as the large between- subjects and within-subject variability, points out the methodologic drawbacks of short-duration therapeutic trials in patients with AD and the challenges in demonstrating reliable treatment effects for potential therapeutic agents.",
author = "Knopman, {David S} and Stephen Gracon",
year = "1994",
month = "2",
language = "English (US)",
volume = "44",
pages = "260--265",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Observations on the short-term 'natural history' of probable Alzheimer's disease in a controlled clinical trial

AU - Knopman, David S

AU - Gracon, Stephen

PY - 1994/2

Y1 - 1994/2

N2 - We examined the performance of patients with probable Alzheimer's disease (AD) who participated in the placebo arm of a 12-week clinical trial. Assessments occurred at baseline and at 4, 6, 10, and 12 weeks after starting study medication. Patients received the Alzheimer's Disease Assessment Scale- Cognitive on all five occasions and the Mini-Mental State Examination on three occasions (baseline, week 6, and week 12). Their primary caregivers completed the Progressive Deterioration Scale on all five visits. This self- administered questionnaire consists of 29 items regarding the patient's behavioral and functional status. The extrapolated yearly rate of change of the mental status examinations was considerably smaller than expected compared with uncontrolled natural history studies. In addition, there was a large within-subject variability on all three measures. Scores from the baseline assessments contributed more to the variability than did the later assessments. The small magnitude of change, as well as the large between- subjects and within-subject variability, points out the methodologic drawbacks of short-duration therapeutic trials in patients with AD and the challenges in demonstrating reliable treatment effects for potential therapeutic agents.

AB - We examined the performance of patients with probable Alzheimer's disease (AD) who participated in the placebo arm of a 12-week clinical trial. Assessments occurred at baseline and at 4, 6, 10, and 12 weeks after starting study medication. Patients received the Alzheimer's Disease Assessment Scale- Cognitive on all five occasions and the Mini-Mental State Examination on three occasions (baseline, week 6, and week 12). Their primary caregivers completed the Progressive Deterioration Scale on all five visits. This self- administered questionnaire consists of 29 items regarding the patient's behavioral and functional status. The extrapolated yearly rate of change of the mental status examinations was considerably smaller than expected compared with uncontrolled natural history studies. In addition, there was a large within-subject variability on all three measures. Scores from the baseline assessments contributed more to the variability than did the later assessments. The small magnitude of change, as well as the large between- subjects and within-subject variability, points out the methodologic drawbacks of short-duration therapeutic trials in patients with AD and the challenges in demonstrating reliable treatment effects for potential therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=0028209623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028209623&partnerID=8YFLogxK

M3 - Article

C2 - 8309570

AN - SCOPUS:0028209623

VL - 44

SP - 260

EP - 265

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -